|
Center No. |
Center Name |
Researchers |
Cases of Experiment Group |
Cases of Control Group |
|
01 |
The First Affiliated Hospital of Zhengzhou University |
Guan Sheng |
10 |
10 |
|
03 |
Beijing Tiantan Hospital CMU |
Cao Yong |
/ |
/ |
|
05 |
The First Hospital of Hebei Medical University |
Conghui Li |
2 |
2 |
|
06 |
General Hospital of Northern Theater Command |
GUobiao Liang |
10 |
10 |
|
07 |
Nanfang Hospital Southern Medical University |
Wenfeng Feng |
2 |
3 |
|
08 |
West China Hospital of Sichuan University |
Zhaohua Wang |
6 |
7 |
|
14 |
Wuhan Union Hospital of China |
Xuebin Hu |
6 |
5 |
|
19 |
Zhuhai People’s Hospital |
Guangshen cheng |
2 |
0 |
|
8 Centers |
38 |
37 |
||
The 75 enrolled cases (38 cases in the test group and 37 cases in the control group) were successfully embolized and withdrawn smoothly, and the embolization success rate was 100%.
Director Haowen Xu of the First Affiliated Hospital of Zhengzhou University concluded: The LAVA liquid embolic system has excellent visibility and dispersibility, especially LAVA-12 can diffuse to deeper parts to complete the embolization, while the microcatheter cannot penetrate deep into the lesion, Which is better than prepared diluted embolic agents by drs themselves. When combined with DAVF embolization, the advantages of its dispersibility are more reflected. In terms of use, the LAVA liquid embolization system uses more micronized grain size of Tantalum powder than ONYX, and the resistance is smaller when pushing. In general, the LAVA liquid embolization system is an excellent product with good market development prospects.
8 Centers Clinical Effect Summary as Below:
1. LAVA is a liquid embolic agent with superior performance .
2. With high, medium and low degrees of viscosity, it accomodates to various clinical requirements.
3. Low injection resistance.
4. Excellent visibility and dispersibility.
5. Extubation is easier.